237 related articles for article (PubMed ID: 29131327)
1. CGRP and PTX3 as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine: An Observational Study.
Domínguez C; Vieites-Prado A; Pérez-Mato M; Sobrino T; Rodríguez-Osorio X; López A; Campos F; Martínez F; Castillo J; Leira R
Headache; 2018 Jan; 58(1):78-87. PubMed ID: 29131327
[TBL] [Abstract][Full Text] [Related]
2. CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine.
Cernuda-Morollón E; Martínez-Camblor P; Ramón C; Larrosa D; Serrano-Pertierra E; Pascual J
Headache; 2014 Jun; 54(6):987-95. PubMed ID: 24673487
[TBL] [Abstract][Full Text] [Related]
3. OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine.
Cernuda-Morollón E; Ramón C; Martínez-Camblor P; Serrano-Pertierra E; Larrosa D; Pascual J
Pain; 2015 May; 156(5):820-824. PubMed ID: 25735000
[TBL] [Abstract][Full Text] [Related]
4. Iron Deposits in Periaqueductal Gray Matter Are Associated with Poor Response to OnabotulinumtoxinA in Chronic Migraine.
Domínguez Vivero C; Leira Y; Saavedra Piñeiro M; Rodríguez-Osorio X; Ramos-Cabrer P; Villalba Martín C; Sobrino T; Campos F; Castillo J; Leira R
Toxins (Basel); 2020 Jul; 12(8):. PubMed ID: 32731573
[TBL] [Abstract][Full Text] [Related]
5. Mild systemic inflammation enhances response to OnabotulinumtoxinA in chronic migraineurs.
Leira Y; Domínguez C; Ameijeira P; López-Arias E; Ávila-Gómez P; Pérez-Mato M; Sobrino T; Campos F; Blanco J; Leira R
Sci Rep; 2021 Jan; 11(1):1092. PubMed ID: 33441852
[TBL] [Abstract][Full Text] [Related]
6. Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year.
Aicua-Rapun I; Martínez-Velasco E; Rojo A; Hernando A; Ruiz M; Carreres A; Porqueres E; Herrero S; Iglesias F; Guerrero AL
J Headache Pain; 2016 Dec; 17(1):112. PubMed ID: 27957623
[TBL] [Abstract][Full Text] [Related]
7. An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine.
Cady R; Turner I; Dexter K; Beach ME; Cady R; Durham P
Headache; 2014 Feb; 54(2):269-77. PubMed ID: 24147647
[TBL] [Abstract][Full Text] [Related]
8. Wear-Off of OnabotulinumtoxinA Effect Over the Treatment Interval in Chronic Migraine: A Retrospective Chart Review With Analysis of Headache Diaries.
Ruscheweyh R; Athwal B; Gryglas-Dworak A; Frattale I; Latysheva N; Ornello R; Pozo-Rosich P; Sacco S; Torres Ferrus M; Stark CD
Headache; 2020 Sep; 60(8):1673-1682. PubMed ID: 32797631
[TBL] [Abstract][Full Text] [Related]
9. Association Between Personality Traits and Onabotulinumtoxin A Response in Patients With Chronic Migraine.
Gonzalez-Martinez A; Rodríguez Vázquez E; de la Red Gallego H; García-Azorín D; Gallego de La Sacristana M; Guerrero Peral ÁL; Gago-Veiga AB
Headache; 2020 Jan; 60(1):153-161. PubMed ID: 31691958
[TBL] [Abstract][Full Text] [Related]
10. Can calcitonin gene-related peptide (CGRP) and pentraxin-3 (PTX-3) be useful in diagnosing acute migraine attack?
Vural S; Albayrak L
J Recept Signal Transduct Res; 2022 Dec; 42(6):562-566. PubMed ID: 35895308
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal.
Lee MJ; Lee SY; Cho S; Kang ES; Chung CS
J Headache Pain; 2018 Jul; 19(1):53. PubMed ID: 30006780
[TBL] [Abstract][Full Text] [Related]
12. Severe periodontitis is linked with increased peripheral levels of sTWEAK and PTX3 in chronic migraineurs.
Leira Y; Ameijeira P; Domínguez C; López-Arias E; Ávila-Gómez P; Pérez-Mato M; Sobrino T; Campos F; D'Aiuto F; Leira R; Blanco J
Clin Oral Investig; 2020 Feb; 24(2):597-606. PubMed ID: 31111284
[TBL] [Abstract][Full Text] [Related]
13. Onabotulinumtoxin-A in Chronic Migraine: Should Timing and Definition of Non-Responder Status Be Revised? Suggestions From a Real-Life Italian Multicenter Experience.
Vernieri F; Paolucci M; Altamura C; Pasqualetti P; Mastrangelo V; Pierangeli G; Cevoli S; D'Amico D; Grazzi L
Headache; 2019 Sep; 59(8):1300-1309. PubMed ID: 31454075
[TBL] [Abstract][Full Text] [Related]
14. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine.
Cernuda-Morollón E; Larrosa D; Ramón C; Vega J; Martínez-Camblor P; Pascual J
Neurology; 2013 Oct; 81(14):1191-6. PubMed ID: 23975872
[TBL] [Abstract][Full Text] [Related]
15. Serum CGRP, VIP, and PACAP usefulness in migraine: a case-control study in chronic migraine patients in real clinical practice.
Pérez-Pereda S; Toriello-Suárez M; Ocejo-Vinyals G; Guiral-Foz S; Castillo-Obeso J; Montes-Gómez S; Martínez-Nieto RM; Iglesias F; González-Quintanilla V; Oterino A
Mol Biol Rep; 2020 Sep; 47(9):7125-7138. PubMed ID: 32951099
[TBL] [Abstract][Full Text] [Related]
16. Wearing Off Response to OnabotulinumtoxinA in Chronic Migraine: Analysis in a Series of 193 Patients.
Quintas S; García-Azorín D; Heredia P; Talavera B; Gago-Veiga AB; Guerrero ÁL
Pain Med; 2019 Sep; 20(9):1815-1821. PubMed ID: 30657951
[TBL] [Abstract][Full Text] [Related]
17. [Frequent episodic migraine and calcitonin gene-related peptide. Influence of treatment with topiramate and zonisamide on levels of the peptide].
Garcia-Estevez DA; Pardo-Parrado M; Silvarrey-Rodriguez S
Rev Neurol; 2017 Aug; 65(4):153-156. PubMed ID: 28726232
[TBL] [Abstract][Full Text] [Related]
18. The effects of vitamin D supplementation on interictal serum levels of calcitonin gene-related peptide (CGRP) in episodic migraine patients: post hoc analysis of a randomized double-blind placebo-controlled trial.
Ghorbani Z; Rafiee P; Fotouhi A; Haghighi S; Rasekh Magham R; Ahmadi ZS; Djalali M; Zareei M; Razeghi Jahromi S; Shahemi S; Mahmoudi M; Togha M
J Headache Pain; 2020 Feb; 21(1):22. PubMed ID: 32093657
[TBL] [Abstract][Full Text] [Related]
19. [Clinical experience of treatment with onabotulinumtoxin A in patients with refractory migraine].
Palma JA; Irimia P; Fernandez-Torron R; Ortega-Cubero S; Riverol M; Luquin MR; Martinez-Vila E
Rev Neurol; 2012 Jun; 54(12):705-11. PubMed ID: 22673946
[TBL] [Abstract][Full Text] [Related]
20. Pentraxin 3 (PTX3): A Molecular Marker of Endothelial Dysfunction in Chronic Migraine.
Domínguez-Vivero C; Leira Y; López-Ferreiro A; Saavedra M; Rodríguez-Osorio X; Sobrino T; Campos F; Castillo J; Leira R
J Clin Med; 2020 Mar; 9(3):. PubMed ID: 32244987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
